

Andrew Weickhardt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12060090/publications.pdf>

Version: 2024-02-01

8

papers

833

citations

1478505

6

h-index

1720034

7

g-index

8

all docs

8

docs citations

8

times ranked

1212

citing authors

#	ARTICLE	IF	CITATIONS
1	Beyond cabazitaxel: Late line treatments in metastatic castration resistant prostate cancer: A retrospective multicentre analysis. Asia-Pacific Journal of Clinical Oncology, 2022, 18, 642-649.	1.1	4
2	[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet, The, 2021, 397, 797-804.	13.7	552
3	Pancreatic mass in a patient undergoing immunotherapy for metastatic renal cell carcinoma: dilemmas in management. ANZ Journal of Surgery, 2021, , .	0.7	0
4	Nivolumab resulting in persistently elevated troponin levels despite clinical remission of myocarditis and myositis in a patient with malignant pleural mesothelioma: case report. Translational Lung Cancer Research, 2020, 9, 360-365.	2.8	13
5	Reproducibility and Repeatability of Semiquantitative ¹⁸ F-Fluorodihydrotestosterone Uptake Metrics in Castration-Resistant Prostate Cancer Metastases: A Prospective Multicenter Study. Journal of Nuclear Medicine, 2018, 59, 1516-1523.	5.0	20
6	Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with <i>BRAF</i> V600 α mutant tumours. British Journal of Clinical Pharmacology, 2018, 84, 764-775.	2.4	13
7	Prognostic impact and the relevance of <i>PTEN</i> copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumab. Cancer Medicine, 2013, 2, 277-285.	2.8	33
8	Impact of <i>KRAS</i> and <i>BRAF</i> Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer. Journal of Clinical Oncology, 2011, 29, 2675-2682.	1.6	198